This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignees: Historx, Inc., Radiation Therapy Oncology Group of the American College of Radiology. Active years: 2013.
Company Filing History:
1 out of 17 
1 out of 1 Years Active: 2013
Title: Annette Molinaro: Innovator in Molecular Markers and Clinical Outcomes
Introduction
Annette Molinaro is a distinguished inventor based in New Haven, CT (US). She has made significant contributions to the field of molecular biology, particularly in understanding the correlation of molecular markers with clinical outcomes in patients with glioblastoma multiforme (GBM). Her innovative work has implications for treatment strategies and patient prognosis.
Latest Patents
Annette holds a patent titled "Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib." This patent highlights the differences in significant biomarkers for Gefitinib-treated GBM patients compared to those who were not treated with this drug. The findings indicate that in Gefitinib-treated patients, higher levels of nuclear pAKT driven by PTEN loss, along with higher levels of nuclear pMAPK and lower levels of nuclear pmTOR, correlate with significantly worse clinical outcomes. Conversely, in non-Gefitinib-treated patients, those with PTEN-deficiency and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB, and lower levels of nuclear Survivin exhibited adverse clinical outcomes. This research underscores the treatment-dependency of these biomarkers.
Career Highlights
Throughout her career, Annette has worked with notable organizations such as Historx, Inc. and the Radiation Therapy Oncology Group of the American College of Radiology. Her work has been pivotal in advancing the understanding of molecular markers in cancer treatment.
Collaborations
Annette has collaborated with esteemed colleagues, including Arnab Chakravarti and Robert Pinard. These partnerships have enriched her research and contributed to the advancement of knowledge in her field.
Conclusion
Annette Molinaro's innovative work in the correlation of molecular markers with clinical outcomes has made a significant impact in the field of oncology. Her contributions continue to influence treatment strategies for GBM patients, highlighting the importance of personalized medicine.